Healthcare – Cigna teams up with Oscar, Qiagen teams up with Amgen

医疗保健精选——信诺与奥斯卡健保合作,Qiagen与安进合作
Published on: January 13, 2020
Author: Amy Liu

Cigna teams up with Oscar in small business health insurance

Cigna (NYSE:CI) has agreed to exclusively partner with tech-driven health insurer Oscar to jointly offer commercial health solutions to small businesses. The effort will branded as “Cigna + Oscar.”

Features:

Integrated medical, behavioral, and pharmacy services.

Broad access to high-performing networks of doctors and hospitals.

Support from a dedicated concierge team assigned to individual members to help them understand their benefits and find care.

Digital-first support, featuring 24/7 telemedicine at no charge, easy ID card access, an overview of copay details and benefits, deductible tracking, lab results and individual health history.

Easy-to-use search tools to help review health care providers, book appointments, find facilities and check prescriptions.

Leading broker, business and provider portals for seamless enrollment and management.

The companies will equally share risk under a reinsurance agreement. Limited launch should commence this year.

Qiagen teams up with Amgen on companion diagnostic for AMG 510

QIAGEN N.V. (NYSE:QGEN) will collaborate with Amgen (NASDAQ:AMGN) to develop a tissue-based companion diagnostic for cancer candidate AMG 510. The initial work will focus on non-small cell lung cancer but the agreement allows for development for other indications.

Financial terms are not disclosed.

Ligand Pharma out-licenses OmniAb platform to Pandion

Ligand Pharmaceuticals (NASDAQ:LGND) inks an agreement with Pandion Therapeutics granting the latter a non-exclusive global license to its OmniAb antibody discovery platform.

Under the terms of the deal, Ligand will receive an upfront fee, milestones and royalties on net sales. Specific financial terms remain confidential.

J&J to collaborate with Exonate in eye diseases

Johnson & Johnson (JNJ +0.3%) unit Janssen Pharmaceutical Companies inks a collaboration agreement with privately held UK biotech Exonate aimed at developing an mRNA-targeted eye drop for retinal vascular diseases such as wet AMD and diabetic macular edema.

Financial terms are not disclosed.

Coherus acquires U.S. rights to Avastin biosimilar

Coherus BioSciences (CHRS -2%) inks an agreement Chinese biotech Innovent Biologics for U.S. and Canadian commercialization rights to the latter’s biosimilar to Roche’s (OTCQX:RHHBY +0.2%) cancer med Avastin (bevacizumab).

It plans to file a U.S. marketing application in Q4 or Q1 2021.

Under the terms of the agreement, Coherus will pay Innovent up to $45M in upfront and milestone fees and double-digit royalties on net sales.

It also has the option to acquire U.S. and Canadian commercialization rights to Innovent’s Rituxan biosimilar. If it exercises the option, the financial terms will be the same as the Avastin deal.

Biotechnology Genomics Healthcare Services Life Science